PURPOSE: The objectives of this study were: (1) to describe parents and health care professionals (HCPs) perceived importance of oral mucositis prevention in children with cancer; (2) To describe utilities and willingness-to-pay (WTP) to prevent mucositis. METHODS: Respondents included parents of children receiving intensive chemotherapy for leukemia/lymphoma or undergoing stem cell transplantation and HCPs caring for children with cancer. Importance of mild and severe oral mucositis was estimated using a visual analogue scale (VAS). Mucositis-associated utilities were elicited using the time trade-off technique (TTO). WTP to avoid mucositis was obtained using contingent valuation. These techniques quantify how much time or money the participant is willing to relinquish in order to prevent mucositis. RESULTS: Eighty-two parents and 60 HCPs were included. Parents and HCPs believed mild mucositis to be of similar importance (median VAS 2.5 versus 3.6; P = 0.357) while parents considered severe mucositis less important than HCPs (median VAS 8.3 versus 9.0; P < 0.0001). No differences in parent versus HCP responses were seen with TTO (mild or severe mucositis) and most parents were not willing to trade any survival time to prevent severe mucositis. Parents were willing to pay significantly more than HCPs to prevent mild mucositis (average median WTP $1,371 CAN vs. $684 CAN, P = 0.031). No differences were seen in WTP to prevent severe mucositis. CONCLUSIONS: Parents and HCP believe severe mucositis to be important, although it is more important to HCPs. Parents would not be willing to reduce life expectancy to eliminate mucositis.
PURPOSE: The objectives of this study were: (1) to describe parents and health care professionals (HCPs) perceived importance of oral mucositis prevention in children with cancer; (2) To describe utilities and willingness-to-pay (WTP) to prevent mucositis. METHODS: Respondents included parents of children receiving intensive chemotherapy for leukemia/lymphoma or undergoing stem cell transplantation and HCPs caring for children with cancer. Importance of mild and severe oral mucositis was estimated using a visual analogue scale (VAS). Mucositis-associated utilities were elicited using the time trade-off technique (TTO). WTP to avoid mucositis was obtained using contingent valuation. These techniques quantify how much time or money the participant is willing to relinquish in order to prevent mucositis. RESULTS: Eighty-two parents and 60 HCPs were included. Parents and HCPs believed mild mucositis to be of similar importance (median VAS 2.5 versus 3.6; P = 0.357) while parents considered severe mucositis less important than HCPs (median VAS 8.3 versus 9.0; P < 0.0001). No differences in parent versus HCP responses were seen with TTO (mild or severe mucositis) and most parents were not willing to trade any survival time to prevent severe mucositis. Parents were willing to pay significantly more than HCPs to prevent mild mucositis (average median WTP $1,371 CAN vs. $684 CAN, P = 0.031). No differences were seen in WTP to prevent severe mucositis. CONCLUSIONS: Parents and HCP believe severe mucositis to be important, although it is more important to HCPs. Parents would not be willing to reduce life expectancy to eliminate mucositis.
Authors: S T Sonis; G Oster; H Fuchs; L Bellm; W Z Bradford; J Edelsberg; V Hayden; J Eilers; J B Epstein; F G LeVeque; C Miller; D E Peterson; M M Schubert; F K Spijkervet; M Horowitz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Erinn T Rhodes; Lisa A Prosser; Tracy A Lieu; Thomas J Songer; David S Ludwig; Lori M Laffel Journal: Pediatr Diabetes Date: 2011-04-13 Impact factor: 4.866
Authors: S L C Figliolia; D T Oliveira; M C Pereira; J R P Lauris; A R Maurício; D T Oliveira; M L Mello de Andrea Journal: Oral Dis Date: 2008-08-22 Impact factor: 3.511
Authors: Lisa A Bellm; Gail Cunningham; Laurie Durnell; June Eilers; Joel B Epstein; Tom Fleming; Henry J Fuchs; Martha Nash Haskins; Mary M Horowitz; Paul J Martin; Deborah B McGuire; Kevin Mullane; Gerry Oster Journal: Cancer Invest Date: 2002 Impact factor: 2.176
Authors: Tiago Nava; Marc Ansari; Jean-Hugues Dalle; Christina Diaz de Heredia; Tayfun Güngör; Eugenia Trigoso; Ulrike Falkenberg; Alice Bertaina; Brenda Gibson; Andrea Jarisch; Adriana Balduzzi; Halvard Boenig; Gergely Krivan; Kim Vettenranta; Toni Matic; Jochen Buechner; Krzysztof Kalwak; Anita Lawitschka; Akif Yesilipek; Giovanna Lucchini; Christina Peters; Dominik Turkiewicz; Riitta Niinimäki; Tamara Diesch; Thomas Lehrnbecher; Petr Sedlacek; Daphna Hutt; Arnaud Dalissier; Jacek Wachowiak; Isaac Yaniv; Jerry Stein; Koray Yalçin; Luisa Sisinni; Marco Deiana; Marianne Ifversen; Michaela Kuhlen; Roland Meisel; Shahrzad Bakhtiar; Simone Cesaro; Andre Willasch; Selim Corbacioglu; Peter Bader Journal: Bone Marrow Transplant Date: 2020-02-06 Impact factor: 5.483
Authors: Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: S Jacobs; C Baggott; R Agarwal; T Hesser; T Schechter; P Judd; D Tomlinson; J Beyene; L Sung Journal: Br J Cancer Date: 2013-10-15 Impact factor: 7.640
Authors: Lillian Sung; Paula Robinson; Nathaniel Treister; Tina Baggott; Paul Gibson; Wim Tissing; John Wiernikowski; Jennifer Brinklow; L Lee Dupuis Journal: BMJ Support Palliat Care Date: 2015-03-27 Impact factor: 3.568
Authors: Karin Melanie Cabanillas Stanchi; Martin Ebinger; Ulrike Hartmann; Manon Queudeville; Judith Feucht; Michael Ost; Marie-Sarah Koch; Carmen Malaval; Markus Mezger; Sarah Schober; Simone Weber; Sebastian Michaelis; Veit Lange; Peter Lang; Rupert Handgretinger; Michaela Döring Journal: Drug Des Devel Ther Date: 2019-09-30 Impact factor: 4.162